Mineralys Therapeutics (MLYS) executive compensation, 2026 proxy

Jon Congleton, President and Chief Executive Officer, was paid $5.5M in 2025, up 2% from $5.4M the year before.

Filed
April 8, 2026
Annual meeting
May 21, 2026
Pay year
2025
Named executives
3
CEO total pay
$5.5M+2% vs prior year
CEO 2025 Base Salary
$636,500Determined by board effective January 1
CEO Target Bonus Percentage
55%Percentage of annual base salary
Bonus Payout Percentage
135%Of bonus target for 2025

How Congleton was paid

$5.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Option awards80%Non-equity incentive9%

Named executive officers

ExecutiveTotal
Jon CongletonPresident and Chief Executive Officer$5,544,727
Adam LevyChief Financial Officer and Secretary$2,203,096
David Rodman, M.D.Chief Medical Officer$2,204,704

What changed and why

  • $5.5MJon Congleton received total compensation of $5,544,727 in fiscal 2025.
  • $637KJon Congleton received a base salary of $636,500 during fiscal 2025.
  • $4.4MOption awards for Jon Congleton totaled $4,435,626 in fiscal 2025.
  • $473KNon-equity incentive plan compensation for Jon Congleton was $472,601 in fiscal 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.